Background Direct factor Xa inhibitors (FXaIs) account for most oral anticoagulant use and
FXaI-associated bleeding events are common. Clinicians have variable national and …

A targeted antidote for reversal of direct factor Xa (FXa) inhibitors is now available for clinical
use in the United States, but it is costly and has limited availability. In a systematic review …

Previous meta‐analyses assessed andexanet alfa (AA) or prothrombin complex concentrate
(PCC) products for the treatment of Factor Xa inhibitor (FXaI)‐associated major bleeding …

Oral factor Xa (fXa) inhibitor-related bleeding is a concerning drug safety problem. There is
considerable controversy surrounding available reversal strategies. The recently approved …

Background Andexanet alfa (andexanet) and prothrombin complex concentrate (PCC) are
both reversal agents for major bleeding in patients using factor Xa inhibitors (FXaIs). Our aim …

Abstract Direct oral factor Xa (FXa) inhibitors are widely used for anticoagulation but a
targeted antidote is not available. Four-factor prothrombin complex concentrate (4FPCC) …

Direct oral anticoagulants (DOACs) are increasingly used for stroke prevention in atrial
fibrillation and treatment and prevention of venous thromboembolism. They are also …

Factor Xa (fXa) inhibitors such as rivaroxaban and apixaban are becoming the
anticoagulants of choice in many clinical contexts. FXa inhibitors are not only more …

Aim: We describe the real-world utilization and outcomes associated with managing oral
factor Xa inhibitor (FXai)-related major bleeds. Materials & methods: Electronic records from …

Bleeding due to oral anticoagulant therapy is recognized as a high priority drug safety
problem [1]. As the use of direct Xa inhibitors continues to expand, the management of …